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Department of Cardiovascular Surgery, Swiss Cardiovascular Centre, University Hospital Bern and University of Bern, Bern, SwitzerlandThis issue of the European Journal of Vascular and Endo-
vascular Surgery features interesting basic research1 that
explores molecular mechanisms behind an important yet
unsolved clinical problem of vascular care: the lost regen-
erative competence of chronically ischaemic wounds. We all
have been challenged by trophic tissue defects in patients
with chronic critical limb ischaemia (CLI) that after some
time seem to turn to an inert state, which may persist even
if revascularisation of the macro-circulation is feasible, not
to speak of situations where it is not. Complementary
regenerative therapy is deﬁnitively needed.
The author’s approach to explore the human hepatocyte
growth factor (HGF)/Met proto-oncogene signalling
pathway is compelling. Activated Met signalling plays an
important role (albeit only in animal models) in numerous
regenerative processes, including skin wound repair,2,3 and
it is indirectly regulated by tissue hypoxia via hypoxia
inducible factor-1 (HIF-1). Consistently, the HGF/Met axis
was indeed downregulated in non-healing CLI wounds in
the present study. The authors saw this as a reﬂection of
decreased HGF serum levels and a local loss of HIF-1 sta-
bility. If this were true, therapeutic application of HGF might
help reactivate normal wound healing in CLI, an intriguing
ﬁnding!
The question, however, is whether the presented data
really suggest such a ﬂy interpretation. The number of
investigated specimens was very limited, and without a
speciﬁc power analysis it remains somewhat unclear how
many parameters were investigated, which increases the
risk of a chance ﬁnding. Moreover, from the snapshot in-
formation alone, it is impossible to determine which came
ﬁrst: the decreased HGF serum levels, the increased HIF-1
RNA expression, or the local loss of c-Met activation?
Thus, already the study design obviates any inference of
causality. But, most importantly, the choice of the control
group may raise concerns. Assuming a localised adverseDOI of original article: http://dx.doi.org/10.1016/j.ejvs.2014.05.002
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use intra-individual controls from regions such as the groin,
where ischaemic wound-healing problems are rare even in
CLI patients. Of note, all patients had either a surgical or an
interventional access in the groin during revascularisation.
Of course, such paired controls would not remove the
challenge of comparing “healthy” skin having suffered a
hyperacute surgical wound with a chronically inert tissue
defect, but at least, it would adjust for other confounding
factors that may bias the present study.
Instead, the authors used samples from patients under-
going abdominal aortic aneurysm repair for understandable
practical reasons. Yet, there is evidence that serum HGF is
generally increased in cardiovascular thrombosis4 and that
HGF may originate in aneurysm tissue,5 both of which may
partly explain the observed relative lack of serum HGF in
CLI. Moreover, the regulation of local tissue healing may not
be as simplistic. Imbalanced protease activity in chronic
non-healing wounds may compromise HGF (or its biological
effects) locally through many interactions.6,7 Therefore,
even if the present observations were clinically relevant, it
remains doubtful whether simple addition of HGF could tip
the balance towards normal wound healing again. At any
rate, accordant attempts have not been successful previ-
ously, as the authors point out correctly.
Thus, the present work only scratches the surface of a
very complex topic. It should be seen as an interesting
hypothesis generating pilot exploration, but certainly not as
a proof of concept already justifying clinical experimental
research. A lot of basic research, further explaining the
mechanisms and of translational work exploring their rele-
vance in clinical reality is needed before regenerative
medicine will enrich the armamentarium of vascular sur-
geons. Hopefully, this paper will provide an impetus for
such studies.REFERENCES
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